News Lilly's Alzheimer's drug Kisunla is cleared in China Eli Lilly has another approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest drugs market.
News uniQure rockets on map to market for Huntington's therapy uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.
News GSK builds neuro, cancer pipeline with trio of deals GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.
News End looms for Cassava's simufilam in Alzheimer's disease Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end
News Sage wilts as Huntington's prospect flunks trial Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for Huntington's disease
News Lexeo shares dip on early data with Alzheimer's gene therapy Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face